Request for Covid-19 Impact Assessment of this Report

Pharmaceuticals

Peripheral Artery Disease Market by Type (Peripheral Angioplasty Balloons, Peripheral Stents, Peripheral Catheters, Inferior Vena Cava (IVC) Filters, Plaque Modification Devices, Hemodynamic Flow Alteration Devices, and Peripheral Accessories): Global Opportunity Analysis and Industry Forecast, 2020–2027

  • ALL4001208
  • 229 Pages
  • July 2020
  • Pharmaceuticals
Download Sample    Get Discount   
 
The global peripheral artery disease market accounted for $3,524.77 million in 2019, and is expected to reach $5,715.12 million by 2027, registering a CAGR of 8.5% from 2020 to 2027.

Peripheral artery disease (PAD) is a disease of blood vessels located outside the brain and heart. PAD occurs when plaque builds up in arteries that carry blood to the head, organs, and limbs. Plaque is made of fat, cholesterol, calcium, fibrous tissue, and other substances. PAD usually affects arteries in the legs, but it can also affect arteries that carry blood from heart to head, arms, kidneys, and stomach.

Factors such as rapid growth in geriatric population and subsequent increase in prevalence of peripheral artery diseases, along with increase in product approvals drive growth of the peripheral artery disease market. However, product recalls and hamper the market growth. Furthermore, increase in incidences of population suffering from diabetes and high blood pressure, which poses a high-risk factor for peripheral artery disease drives the market growth. In addition, favorable reimbursement scenario for peripheral artery disease treatment and introduction of advanced treatment products such as drug-eluting stents boost the market growth. However, issue of restenosis (reoccurrence of peripheral artery disease even after treatment) impedes the market growth.

Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in 2019, and is expected to retain its dominance throughout the forecast period. This is attributed to factors such as well-equipped & better financed hospitals & clinics, high adoption rate of peripheral artery disease products, and sophisticated healthcare infrastructure. Moreover, the U.S. is the target area for top players in the market, owing to high awareness regarding PAD devices. However, Asia-Pacific and LAMEA are expected to emerge as a lucrative areas with maximum growth potential, owing to improvement in healthcare facilities, available disposable income, and rapidly developing economic conditions.

The global peripheral artery disease market is segmented on the basis of type and region. On the basis of type, the market is divided into peripheral angioplasty balloons, peripheral stents, peripheral catheters, inferior vena cava (IVC) filters, plaque modification devices, hemodynamic flow alteration devices, and peripheral accessories. By region, the market is studied across North America (U.S., Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, India, China, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA)

The key companies operating in the market include Abbott Laboratories, Boston Scientific Corporation, Cook Medical, Cardinal Health, Inc., Becton, Dickinson and Company, Terumo Corporation, Koninklijke Philips N.V, AngioDynamics, Inc., BIOTRONIK, and B. Braun Melsungen AG.

KEY BENEFITS FOR STAKEHOLDERS

• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.

• It offers a quantitative analysis from 2019 to 2027, which is expected to enable stakeholders to capitalize on prevailing market opportunities.

• The key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By type

• Peripheral Angioplasty Balloons

o Old/Normal Balloons

o Cutting and Scoring Balloons

o Drug-Coated Balloons

• Peripheral Stents

o Self-expandable

o Balloon-expandable

o Covered

o Drug-eluting Stents

• Peripheral Catheters

o Angiography Catheters

o Guiding Catheters

• Inferior Vena Cava (IVC) Filters

o Permanent Filters

o Retrievable Filters

• Plaque Modification Devices

o Thrombectomy Devices

 Mechanical Thrombectomy Devices

 Aspiration Thrombectomy Devices

 Rheolytic Thrombectomy Devices

o Atherectomy Devices

• Hemodynamic Flow Alteration Devices

o Embolic Protection Devices

o Chronic Total Occlusion Devices

• Peripheral Accessories

o Vascular Closure Devices

o Introducer Sheaths

o Guidewires

o Balloon Inflation Devices

By Region

North America

• U.S.

• Canada

• Mexico

Europe

• Germany

• UK

• France

• Italy

• Spain

• Rest of Europe

Asia-Pacific

• Japan

• China

• India

• Australia

• Rest of Asia-Pacific

LAMEA

• Brazil

• Saudi Arabia

• South Africa

• Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

• Abbott Laboratories

• AngioDynamics

• B. Braun Melsungen AG

• Becton, Dickinson and Company

• Boston Scientific Corporation

• BIOTRONIK

• Cook Medical

• Cardinal Health, Inc.

• Koninklijke Philips N.V

• TERUMO CORPORATION.

CHAPTER 1:INTRODUCTION

1.1.Report description

1.2.Key market segments

1.2.1.List of key players profiled in the report

1.3.Research methodology

1.3.1.Primary research

1.3.2.Secondary research

1.3.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study

2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope

3.2.Top winning strategies, 2019

3.3.Top player positioning

3.3.1.Top investment pockets

3.4.Key forces shaping peripheral artery disease industry/market

3.4.1.Drivers

3.4.1.1.Growth in geriatric population and increase in prevalence of peripheral artery disease

3.4.1.2.Introduction of advanced interventional products

3.4.1.3.Improvement of healthcare infrastructure in developing countries

3.4.1.4.Improved insurance and reimbursement policies

3.4.2.Restraints

3.4.2.1.Restenosis

3.4.2.2.Stringent approval process for stents

3.4.3.Opportunity

3.4.3.1.Market opportunities in developing countries

3.4.4.Impact Analysis

3.5.COVID-19 impact on the market

CHAPTER 4:PERIPHERAL ARTERY DISEASE MARKET, BY TYPE

4.1.Overview

4.1.1.Market size and forecast, by type

4.2.Peripheral Angioplasty Balloons

4.2.1.Key market trends, growth factors, and opportunities

4.2.2.Market size and forecast, by region

4.2.3.Market analysis, by country

4.2.4.Peripheral angioplasty balloons, by type

4.2.4.1.Market size and forecast

4.2.4.2.Old/normal balloons, market size and forecast

4.2.4.3.Cutting & scoring balloons, market size and forecast

4.2.4.4.Drug-coated balloons, market size and forecast

4.3.Peripheral Stents

4.3.1.Key market trends, growth factors, and opportunities

4.3.2.Market size and forecast, by region

4.3.3.Market analysis, by country

4.3.4.Peripheral stent, by type

4.3.4.1.Market size and forecast

4.3.4.2.Self-expandable, market size and forecast

4.3.4.3.Balloon-expandable, market size and forecast

4.3.4.4.Covered stents, market size and forecast

4.3.4.5.Drug-eluting stents, market size and forecast

4.4.Peripheral Catheters

4.4.1.Key market trends, growth factors, and opportunities

4.4.2.Market size and forecast, by region

4.4.3.Market analysis, by country

4.4.4.Peripheral catheters, by type

4.4.4.1.Market size and forecast

4.4.4.2.Angiography catheters, market size and forecast

4.4.4.3.Guiding catheters, market size and forecast

4.5.Inferior Vena Cava (IVC) Filters

4.5.1.Key market trends, growth factors, and opportunities

4.5.2.Market size and forecast, by region

4.5.3.Market analysis, by country

4.5.4.Inferior vena cava (IVC) filters, by type

4.5.4.1.Market size and forecast

4.5.4.2.Permanent filters, market size and forecast

4.5.4.3.Retrievable filters, market size and forecast

4.6.Plaque Modification Devices

4.6.1.Key market trends, growth factors, and opportunities

4.6.2.Market size and forecast, by region

4.6.3.Market analysis, by country

4.6.4.Plaque modification devices, by type

4.6.4.1.Market size and forecast

4.6.4.2.Thrombectomy devices, market size and forecast

4.6.4.3.Thrombectomy devices, By type

4.6.4.4.Thrombectomy devices, market size and forecast, by type

4.6.4.4.1.Mechanical thrombectomy devices, market size and forecast

4.6.4.4.2.Aspiration thrombectomy devices, market size and forecast

4.6.4.4.3.Rheolytic thrombectomy devices, market size and forecast

4.6.4.5.Atherectomy devices, market size and forecast

4.7.Hemodynamic Flow Alteration Devices

4.7.1.Key market trends, growth factors, and opportunities

4.7.2.Market size and forecast, by region

4.7.3.Market analysis, by country

4.7.4.Hemodynamic flow alteration devices, By type

4.7.4.1.Market size and forecast

4.7.4.2.Embolic protection devices, market size and forecast

4.7.4.3.Chronic total occlusion devices, market size and forecast

4.8.Peripheral Accessories

4.8.1.Key market trends, growth factors, and opportunities

4.8.2.Market size and forecast, by region

4.8.3.Market analysis, by country

4.8.4.Peripheral Accessories, By type

4.8.4.1.Market size and forecast

4.8.4.2.Peripheral vascular closure devices, market size and forecast

4.8.4.3.Introducer sheaths, market size and forecast

4.8.4.4.Guidewires, market size and forecast

4.8.4.5.Balloon inflation devices, market size and forecast

CHAPTER 5:PERIPHERAL ARTERY DISEASE MARKET, BY REGION

5.1.Overview

5.1.1.Market size and forecast, by region

5.2.North America

5.2.1.Key market trends, growth factors, and opportunities

5.2.2.Market size and forecast, by country

5.2.3.Market size and forecast, by type

5.2.4.U.S.

5.2.5.Canada

5.2.6.Mexico

5.3.Europe

5.3.1.Key market trends, growth factors, and opportunities

5.3.2.Market size and forecast, by country

5.3.3.Market size and forecast, by type

5.3.4.Germany

5.3.5.France

5.3.6.UK

5.3.7.Italy

5.3.8.Spain

5.3.9.Rest of Europe

5.4.Asia-Pacific

5.4.1.Key market trends, growth factors, and opportunities

5.4.2.Market size and forecast, by country

5.4.3.Market size and forecast, by type

5.4.4.Japan

5.4.5.China

5.4.6.India

5.4.7.Australia

5.4.8.Rest of Asia-Pacific

5.5.LAMEA

5.5.1.Key market trends, growth factors, and opportunities

5.5.2.Market size and forecast, by country

5.5.3.Market size and forecast, by type

5.5.4.Brazil

5.5.5.South Africa

5.5.6.Saudi Arabia

5.5.7.Rest of LAMEA

CHAPTER 6:COMPANY PROFILES

6.1.ABBOTT LABORATORIES

6.1.1.Company overview

6.1.2.Company snapshot

6.1.3.Operating business segments

6.1.4.Product portfolio

6.1.5.Business performance

6.2.ANGIODYNAMICS, INC.

6.2.1.Company overview

6.2.2.Company snapshot

6.2.3.Operating business segments

6.2.4.Product portfolio

6.2.5.Business performance

6.2.6.Key strategic moves and developments

6.3.B. BRAUN MELSUNGEN AG

6.3.1.Company overview

6.3.2.Company snapshot

6.3.3.Operating business segments

6.3.4.Product portfolio

6.3.5.Business performance

6.4.BIOTRONIK, INC.

6.4.1.Company overview

6.4.2.Company snapshot

6.4.3.Operating business segments

6.4.4.Product portfolio

6.4.5.Key strategic moves and developments

6.5.BOSTON SCIENTIFIC CORPORATION

6.5.1.Company overview

6.5.2.Company snapshot

6.5.3.Operating business segments

6.5.4.Product Portfolio

6.5.5.Business performance

6.6.BECTON, DICKINSON AND COMPANY

6.6.1.Company overview

6.6.2.Company snapshot

6.6.3.Operating business segments

6.6.4.Product portfolio

6.6.5.Business performance

6.6.6.Key strategic moves and developments

6.7.CARDINAL HEALTH, INC.

6.7.1.Company overview

6.7.2.Company snapshot

6.7.3.Operating business segments

6.7.4.Product portfolio

6.7.5.Business performance

6.8.COOK MEDICAL, INC.

6.8.1.Company overview

6.8.2.Company snapshot

6.8.3.Operating business segments

6.8.4.Product portfolio

6.8.5.Key strategic moves and developments

6.9.KONINKLIJKE PHILIPS N.V. (PHILIPS)

6.9.1.Company overview

6.9.2.Company snapshot

6.9.3.Operating business segments

6.9.4.Product portfolio

6.9.5.Business performance

6.9.6.Key strategic moves and developments

6.10.TERUMO CORPORATION

6.10.1.Company overview

6.10.2.Company snapshot

6.10.3.Operating business segments

6.10.4.Product portfolio

6.10.5.Business performance

6.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.GLOBAL PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 02.PERIPHERAL ARTERY DISEASE MARKET FOR PERIPHERAL ANGIOPLASTY BALLOONS, BY REGION, 2019–2027 ($MILLION)

TABLE 03.PERIPHERAL ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 04.PERIPHERAL ARTERY DISEASE MARKET FOR PERIPHERAL STENTS, BY REGION, 2019–2027 ($MILLION)

TABLE 05.PERIPHERAL CATHETERS MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 06.PERIPHERAL ARTERY DISEASE MARKET FOR PERIPHERAL CATHETER, BY REGION, 2019–2027 ($MILLION)

TABLE 07.PERIPHERAL CATHETERS MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 08.PERIPHERAL ARTERY DISEASE MARKET FOR INFERIOR VENA CAVA (IVC) FILTERS, BY REGION, 2019–2027 ($MILLION)

TABLE 09.INFERIOR VENA CAVA (IVC) FILTERS MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 10.PERIPHERAL ARTERY DISEASE MARKET FOR PLAQUE MODIFICATION DEVICES, BY REGION, 2019–2027 ($MILLION)

TABLE 11.PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 12.PERIPHERAL ARTERY DISEASE MARKET FOR HEMODYNAMIC FLOW ALTERATION DEVICES, BY REGION, 2019–2027 ($MILLION)

TABLE 13.HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 14.PERIPHERAL ARTERY DISEASE MARKET FOR PERIPHERAL ACCESSORIES, BY REGION, 2019–2027 ($MILLION)

TABLE 15.PERIPHERAL ACCESSORIES MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 16.PERIPHERAL ARTERY DISEASE MARKET, BY REGION, 2019–2027 ($MILLION)

TABLE 17.NORTH AMERICA PERIPHERAL ARTERY DISEASE MARKET, BY COUNTRY, 2019–2027 ($MILLION)

TABLE 18.NORTH AMERICA PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 19.U.S. PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 20.CANADA PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 21.MEXICO PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 22.EUROPE PERIPHERAL ARTERY DISEASE MARKET, BY COUNTRY, 2019–2027 ($MILLION)

TABLE 23.EUROPE PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 24.GERMANY PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 25.FRANCE PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 26.UK PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 27.ITALY PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 28.SPAIN PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 29.REST OF EUROPE PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 30.ASIA-PACIFIC PERIPHERAL ARTERY DISEASE MARKET, BY COUNTRY, 2019–2027 ($MILLION)

TABLE 31.ASIA-PACIFIC PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 32.JAPAN PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 33.CHINA PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 34.INDIA PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 35.AUSTRALIA PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 36.REST OF ASIA-PACIFIC PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 37.LAMEA PERIPHERAL ARTERY DISEASE MARKET, BY COUNTRY, 2019–2027 ($MILLION)

TABLE 38.LAMEA PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 39.BRAZIL PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 40.SOUTH AFRICA PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 41.SAUDI ARABIA PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 42.REST OF LAMEA PERIPHERAL ARTERY DISEASE MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 43.ABBOTT: COMPANY SNAPSHOT

TABLE 44.ABBOTT: OERATING SEGMENT

TABLE 45.ABBOTT: PRODUCT PORTFOLIO

TABLE 46.ANGIODYNAMICS: COMPANY SNAPSHOT

TABLE 47.ANGIODYNAMICS: OPERATING SEGMENTS

TABLE 48.ANGIODYNAMICS: PRODUCT PORTFOLIO

TABLE 49.B. BRAUN: COMPANY SNAPSHOT

TABLE 50.B. BRAUN: OPERATING SEGMENTS

TABLE 51.B. BRAUN: PRODUCT PORTFOLIO:

TABLE 52.BIOTRONIK, INC..: COMPANY SNAPSHOT

TABLE 53.BIOTRONIK, INC..: OPERATING SEGMENTS

TABLE 54.BIOTRONIK, INC.: PRODUCT PORTFOLIO

TABLE 55.BOSTON SCIENTIFIC: COMPANY SNAPSHOT

TABLE 56.BOSTON SCIENTIFIC: OPERATING SEGMENTS

TABLE 57.BOSTON SCIENTIFIC: PRODUCT PORTFOLIO

TABLE 58.BD: SNAPSHOT

TABLE 59.BD: OPERATING SEGMENTS

TABLE 60.BD: PRODUCT PORTFOLIO

TABLE 61.CARDINAL HEALTH: COMPANY SNAPSHOT

TABLE 62.CARDINAL HEALTH: OPERATING SEGMENTS

TABLE 63.CARDINAL HEALTH: PRODUCT PORTFOLIO

TABLE 64.COOK: COMPANY SNAPSHOT

TABLE 65.COOK: OERATING SEGMENT

TABLE 66.COOK: PRODUCT PORTFOLIO

TABLE 67.PHILIPS: COMPANY SNAPSHOT

TABLE 68.PHILIPS: OPERATING SEGMENTS

TABLE 69.PHILIPS: PRODUCT PORTFOLIO

TABLE 70.TERUMO: COMPANY SNAPSHOT

TABLE 71.TERUMO: OPERATING SEGMENTS

TABLE 72.TERUMO: PRODUCT PORTFOLIO

 
Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Contact Us

+ 1-888-961-4454

Drop Us an email at

help@bigmarketresearch.com

Similar Reports

United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025

The United States pneumococcal & meningococcal vaccines market is set to surpass US$ 7.5 Million by the year end of 2025. “United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025” presents an in–depth assessment of the United States pneumococcal & meningococcal vaccines market dynamics, opportunitie...

  • Publish Date: June 24, 2019
  • $1050
Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts

The global human immunodeficiency virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025. “Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts” presents an in-depth assessment of the global human immunodeficiency virus (HIV) drugs market dynamics, opportunities, future roadmap, competitive landscap...

  • Publish Date: February 18, 2019
  • $1290
Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts

The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025. ‘’Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the m...

  • Publish Date: December 11, 2018
  • $1390